CSL Limited is a biopharmaceutical company engaged in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. It operates in three segments: CSL Behring, which is engaged in manufacturing, marketing and developing plasma products; Intellectual Property Licensing, which is engaged in licensing to unrelated third parties of intellectual property generated by the Company, and Other Human Health, which comprises CSL Bioplasma and CSL Biotherapies. These businesses manufacture and distribute biotherapeutic products. It operates in Australia, United States, Switzerland and Germany.

Purely Proteins doesn't mix your ordinary protein shake. Through its proprietary technology, the company purifies human proteins to accelerate biotherapeutic drug discovery and drug screening. Purely Proteins also operates a subscription-based online database of gene and protein information called TargetBASE, which gives chemists and biologists a summary of known and potential protein targets that may help in the discovery of therapies for diabetes, cancer, and Alzheimer's disease. The company conducts its research in conjunction with several business partners, including Abcam Ltd, Asahi Kasei, Cytomyx Limited, and Inhibox Ltd. CEO David Parry-Smith co-founded Purely Proteins in 2002.

Glycotex wants to see such creatures as ulcers, bed sores, and sunburns put on the Australian endangered species list. The biopharmaceutical company researches and develops products based on molecular glucan receptors that trigger the healing process. Connective tissue repair, skin ulcers, and bone fractures are primary recovery fields for its glucan receptor products. Glycotex's lead product candidate, MG3601, is a topical treatment for ulcers, and it has completed Phase II clinical trials. Other therapeutic candidates include Glucocol and Glucoprime, active ingredients designed to treat tendon regeneration and topical needs, respectively. Its parent company, Novogen, owns 84% of Glycotex.

The pros at ProPharma Partners offer advice to biotechnology and pharmaceutical companies on everything from corporate strategy to clinical trials. The consulting firm, which is the European arm of US-based ProPharma Partners Group, assists companies with negotiating licensing deals, corporate partnerships, and mergers and acquisitions. ProPharma also helps its clients complete FDA regulatory applications in order to register and market newly-developed drug products. The group has offices in North America, Europe, and Japan, from which it serves such clients as Cambridge Laboratories, King Pharmaceuticals, Metabolex, ReGen Therapeutics Plc, and Replidyne.

Kreatech Biotechnology company develops tools used by pharmaceutical companies and medical researchers to detect and label RNA, DNA, and proteins. Its labeling kits, DNA probes, and other products are used in applications such as drug development and the diagnosis of disease. The company's investors include 3i Group, Alafi Capital, and Life Sciences Partners. Kreatech has formed alliances with many pharmaceutical and instrumentation firms, including heavyweights such as GE Healthcare Bio-Sciences and PerkinElmer.

Bellus Health scientists are putting their gray matter to work to find therapies for incurable conditions. Formerly known as Neurochem, Bellus Health's lead candidate is a potential treatment for Amyloid A amyloidosis, an often fatal condition associated with inflammatory disease and kidney dysfunction. Bellus has licensed the late-stage compound to Centocor, which plans to market it under the name Kiacta. Bellus is also evaluating a potential treatment for type 2 diabetes in clinical trials and has discovery programs in the areas of Alzheimer's disease, diabetes, and metabolic syndrome. Its OVOS Natural Health business is touting homotaurine as a nutritional supplement to improve memory and cognition.

Genentech, Inc. (Genentech) is a biotechnology company that discovers, develops, manufactures and commercializes pharmaceutical products to treat patients with unmet medical needs. It commercializes multiple biotechnology products and also receives royalties from companies that are licensed to market products based on the Company’s technology. Genentech commercializes various products in the United States, including Avastin, Rituxan, Herceptin, Lucentis, Xolair, Tarceva, Nutropin, Activase, TNKase, Cathflo Activase, Pulmozyme and Raptiva. The Company’s licensed products include Trastuzumab, Rituximab, Bevacizumab, Dornase alfa, recombinant, Alteplase and Tenecteplase, Somatropin, Daclizumab, Ranibizumab, Etanercept, Adalimumab and Infliximab. In March 2009, Roche Holding Ltd. completed the acquisition of Genentech.

Allergy Research Group Inc. offers nutritional supplement products. It offers amino acids, antioxidant formulas, bioenergetics, bioflavonoids, blood sugar, books, brain, cardiovascular, comprehensive formulas, fatty acids, eye, gastric support, glandulars, and hormone products. Allergy Research Group also provides immune support, liver support, martin pall products, metabolic support, microbial balancers, minerals, multiples, musculoskeletal, probiotics, specialty products, vitamin B products, vitamin C products, and vitamin D, E, K products. The company was founded in 1979 and is headquartered in Alameda, California. As of September 9, 2008, Allergy Research Group Inc. operates as a subsidiary of KI NutriCare, Inc.

Amphastar Pharmaceuticals, Inc. is a generic and specialty pharmaceutical company that is engaged in the discovery, development, manufacture and marketing of generic and proprietary pharmaceuticals, innovative delivery systems and active pharmaceutical ingredients. Amphastar’s Management Team takes pride in the Company’s “3H” commitment to "High Quality, High Efficiency and High Technology". In keeping with this pledge of excellence to the consumer, Amphastar will continue to invest in state-of-the-art equipment, research & development, facilities, and the advancement of their employees.

Genzyme Pharmaceuticals, a division of leading biotech firm Genzyme, couldn't agree more. The division, at its main production facility in Liestal, Switzerland, makes chemical intermediates and active pharmaceutical ingredients used in the production of a number of drugs, many manufactured by its parent. Its main products include natural and synthetic lipids and amino acid derivatives. It has also partnered with major pharmaceutical companies to develop custom manufacturing of drugs currently in development. Additionally, Genzyme Pharmaceuticals manufactures lipid-based drug delivery systems.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.